Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Septarna Inc. (SEPN:NASDAQ), powered by AI.
Septarna Inc. is currently trading at $35.95. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Septarna Inc. on Alpha Lenz.
View Septarna Inc.'s valuation metrics on Alpha Lenz.
“Septarna Inc.'s ROE is -12.2%. Explore profitability and growth together.”
Ask for details →Septarna Inc. is a leading biotechnology company specializing in the development of innovative therapeutic solutions aimed at addressing rare genetic disorders. With a focus on advanced genetic research, the company seeks to pioneer treatments that modify the underlying causes of these conditions, offering hope to patients with limited treatment options. Septarna Inc. harnesses cutting-edge gene editing technologies, positioning itself at the forefront of medical innovation and personalized medicine. The company’s efforts are significant in the healthcare sector, particularly in precision medicine, where tailored treatments are revolutionizing patient care. By collaborating with academic institutions and leveraging a robust intellectual property portfolio, Septarna Inc. contributes to expanding the understanding of genetic diseases and therapeutic approaches. In the financial market, Septarna Inc. is regarded as a key player in the biotechnology industry, attracting attention from stakeholders interested in long-term growth prospects tied to scientific breakthroughs. The company’s research and development endeavors reinforce its role as a beacon of innovation within the niche market of genetic therapies.
“Septarna Inc.'s ROE is -12.2%. Explore profitability and growth together.”
Ask for details →Septarna Inc. (ticker: SEPN) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 75 employees.
The current price is $35.95 with a P/E ratio of -x and P/B of -x.
ROE is -12.19% and operating margin is -175.83%. Annual revenue is $46M.